Strong efficacy and safety data de-risk dabogratinib's registrational path in NMIBC and support expansion into LG UTUC and achondroplasia. Monitor upcoming data from the 70 mg cohort, FDA interactions, and initiation of the Phase 3 adjuvant study in 2027. Positive readthrough for TYRA's FGFR3 franchise value.
Drug in focus
TYRA drug pipeline →dabogratinib
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- Dabogratinib is in Phase 2 development across all three indications. A pivotal Phase 3 study in NMIBC is being planned following the SURF302 data, but no specific start date has been given. The earliest potential approval would likely be several years away, contingent on successful Phase 3 data and FDA review.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the BEACH301 Phase 2 safety sentinel cohort data in pediatric achondroplasia, expected by end of Q1 2027. Positive safety and growth data could re-rate the stock after the September 2026 SURF302 selloff; negative safety signals would damage the achondroplasia thesis. Separately, watch for details on a planned pivotal Phase 3 study in NMIBC, which would be the next major binary event for the bladder cancer program.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 9 $22.01entry
- T+1 · 2mo ago +6.95%α +7.55% · $23.54
- T+5 · 2mo ago +10.63%α +11.73% · $24.35
- T+20 · 6w ago −7.36%α −9.30% · $20.39
- T+48 · todayOpen
- T+60 · in 16d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tyra Biosciences announced positive initial Phase 2 data for oral dabogratinib in FGFR3-altered low-grade intermediate-risk NMIBC, showing 79% ORR and 64% complete response rate at 60 mg QD with favorable safety (no Grade 4/5 AEs, no dose reductions). The company plans to initiate a registrational adjuvant study in 2027, targeting a >$5B market opportunity.
Key Facts
- SURF302 Phase 2 ORR 79% (11/14) at 60 mg QD at 3-month and best overall response; CR 64% (9/14) BOR
- No Grade 4 or 5 treatment-emergent adverse events; Grade 3 TEAEs in 14% at 60 mg; none at 60 mg were treatment-related
- Plans to complete 60 mg enrollment, initiate 70 mg cohort, engage health authorities on Phase 3 design, and start registrational adjuvant study in 2027
- SURF303 first LG UTUC patient achieved CR at 3 months with no TEAEs; BEACH301 cleared fifth dose level in achondroplasia cohort
- Estimated total market opportunity for IR NMIBC >$5 billion per third-party market research
Financial Impact
Market opportunity >$5 billion for IR NMIBC; no revenue or financial data reported
Risk Factors
- Initial clinical data may change as more patients are enrolled and follow-up matures
- Regulatory path and dose selection require alignment with FDA, no guarantee of approval
- Pre-revenue company with cash burn risk and potential future dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-385886 |
| Document: 0001193125-26-385886-index-headers.html | 0001193125-26-385886 |
| Document: 0001193125-26-385886-index.html | 0001193125-26-385886 |
| Document: 0001193125-26-385886.txt | 0001193125-26-385886 |
Track record
13 reports on TYRA
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.37% at T+60 after the Jun 26, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $21.00 Now $19.74 −6.00% settles Nov 17
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $21.75 to $21.53 Now $19.74 −9.24% ▼ −1.03% −0.32% vs SPY
- Sep 21, 20268w ago SC 13G Neutral 4/10 Entry $25.57 to $21.98 Now $19.74 −22.80% ▼ −14.04% −12.85% vs SPY
- Sep 17, 20268w ago Insider Cluster Bullish 8/10 Entry $25.73 to $21.76 Now $19.74 −23.28% ▼ −15.43% −16.70% vs SPY
- Sep 14, 20269w ago S-3ASR Neutral 3/10 Entry $25.07 to $25.65 Now $19.74 −21.26% ▲ +2.31% +2.21% vs SPY
- Sep 9, 20269w ago 8-K Bullish 6/10 Viewing Entry $22.01 to $24.35 Now $19.74 −10.31% ▲ +10.63% +11.73% vs SPY
- Aug 4, 202614w ago 424B5 Bearish 6/10 Entry $25.71 to $25.30 Now $19.74 +23.22% ▲ +1.59% +1.95% vs SPY
- Jun 26, 202620w ago 144 Bearish 6/10 Entry $32.11 to $30.86 Now $19.74 +38.52% ▲ +3.89% +5.28% vs SPY
- May 13, 202626w ago 8-K Mixed 5/10 Entry $36.19 to $33.78 Now $19.74 −45.45% ▼ −6.66% −5.50% vs SPY
- Apr 20, 202630w ago 3 Neutral 2/10 Entry $36.69 to $35.06 Now $19.74 −46.20% ▼ −4.44% −5.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers